Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

0.6469 -0.2681 (-29.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Porch Group And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed lower by over 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
From Enveric Biosciences
Via Business Wire
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
From Enveric Biosciences
Via Business Wire
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time for another dive into the biggest pre-market stock movers as we check out the shares worth watching on Tuesday! 
Via InvestorPlace
Boosting Next-Gen Mental Health Care: Enveric's New US Patent For Anxiety Treatment
The USPTO issued a patent covering Enveric Biosciences’ (NASDAQ: ENVB) lead candidate EB-373, a psilocin prodrug under development for the treatment of anxiety disorder. 
Via Benzinga
Topics Intellectual Property
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs
From Enveric Biosciences
Via Business Wire
Marijuana Stock Movers For August 23, 2023
 
Via Benzinga
Topics Cannabis
Cannabis Stock Gainers And Losers From August 24, 2023
 
Via Benzinga
Topics Cannabis
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Marijuana Stock Movers For August 22, 2023
 
Via Benzinga
Topics Cannabis
Enveric Completes Manufacturing Of Its Psilocin Prodrug To Supply Drug Material For Completion Of Preclinical Program
Enveric Biosciences (NASDAQ: ENVB) has completed manufacturing of drug material enabling the completion of preclinical work for EB-373 including all bioanalytical method validation, GLP toxicology and... 
Via Benzinga
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program
From Enveric Biosciences
Via Business Wire
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
 
Via Benzinga
Topics Cannabis
Enveric's Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024
Next-gen psychedelics business Enveric Biosciences (NASDAQ: ENVB) reported its unaudited financial results for the second quarter of 2023 ended June 30. Results show: 
Via Benzinga
Cannabis Stock Gainers And Losers From August 16, 2023
 
Via Benzinga
Topics Cannabis
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
Marijuana Stock Movers For August 15, 2023
 
Via Benzinga
Topics Cannabis
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
Cannabis Stock Gainers And Losers From August 11, 2023
 
Via Benzinga
Topics Cannabis
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Cannabis Stock Movers For August 3, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.